ReviewCurrent diabetes reports2013
Emerging roles for miRNAs in the development, diagnosis, and treatment of diabetic nephropathy.
Review in Current diabetes reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- miR-543 regulates high glucose-induced fibrosis and autophagy in diabetic nephropathy by targeting TSPAN8.BMC nephrology · 2022Article
- Differential expression of micro RNA-29 family in non-diabetic adults of diabetic and non-diabetic parents.BMC research notes · 2021Article
- miR-206 Inhibits Cell Proliferation and Extracellular Matrix Accumulation by Targeting Hypoxia-Inducible Factor 1-alpha (HIF-1α) in Mesangial Cells Treated with High Glucose.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Epigenetics and epigenomics in diabetic kidney disease and metabolic memory.Nature reviews. Nephrology · 2019Review
- Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease.Kidney research and clinical practice · 2018Review
- Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases.American journal of physiology. Renal physiology · 2016Review
- Integrative Biology of Diabetic Kidney Disease.Kidney diseases (Basel, Switzerland) · 2015Article
- MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.Annals of the New York Academy of Sciences · 2015Review
- Circulating TGF-β1-Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes.Diabetes · 2015Article
- Review
- Diabetic nephropathy--emerging epigenetic mechanisms.Nature reviews. Nephrology · 2014Review
- Exosomal miRNAs as potential biomarkers of cardiovascular risk in children.Journal of translational medicine · 2014Review
- Diabetic nephropathy - complications and treatment.International journal of nephrology and renovascular disease · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the causes of diabetic nephropathy are not yet fully known, emerging evidence suggests a role for epigenetic factors in the development of the disease. In particular, microRNAs (miRNAs) are becoming recognized as important mediators of biological processes relevant to diabetic nephropathy. Until recently, investigations of miRNAs in the development of diabetic nephropathy have remained relatively limited; however, the number of reports identifying potential new candidates and mechanisms of impact is presently expanding at a rapid pace. This review seeks to summarize these recent findings, focusing on new candidates and/or novel mechanisms, including the intersection between genetic variation and miRNA function in modulating disease expression, emerging in the field. We also review the latest advances in the diagnostic and therapeutic potential of miRNAs in the treatment of diabetic nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.